Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer

被引：0
作者：
Baker, Holly
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2021年 / 6卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Modi, Shanu
    Gambhire, Dhiraj
    Cameron, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12) : 1145 - 1146
  • [42] The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis
    Kou, Liqiu
    Chen, Xiu
    Xie, Xiaolu
    Wen, Qinglian
    Li, Jun
    Li, Yaling
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (08) : 722 - 729
  • [43] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.
    Shitara, Kohei
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Yabusaki, Hiroshi
    Iwasa, Satoru
    Sakai, Daisuke
    Muro, Kei
    Sugimoto, Naotoshi
    Yasui, Hisateru
    Gamoh, Makio
    Murakawa, Yasuko
    Negoro, Yuji
    Nishina, Tomohiro
    Hosaka, Hisashi
    Omuro, Yasushi
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [45] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [46] New drugs approval: Trastuzumab- deruxtecan-HER2-low metastatic breast cancer
    Gorgeu, Violaine
    Grellety, Thomas
    BULLETIN DU CANCER, 2023, 110 (06) : 597 - 598
  • [47] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [48] Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
    Mosele, Fernanda
    Deluche, Elise
    Lusque, Amelie
    Le Bescond, Loic
    Filleron, Thomas
    Pradat, Yoann
    Ducoulombier, Agnes
    Pistilli, Barbara
    Bachelot, Thomas
    Viret, Frederic
    Levy, Christelle
    Signolle, Nicolas
    Alfaro, Alexia
    Tran, Diep T. N.
    Garberis, Ingrid Judith
    Talbot, Hugues
    Christodoulidis, Stergios
    Vakalopoulou, Maria
    Droin, Nathalie
    Stourm, Aurelie
    Kobayashi, Maki
    Kakegawa, Tomoya
    Lacroix, Ludovic
    Saulnier, Patrick
    Job, Bastien
    Deloger, Marc
    Jimenez, Marta
    Mahier, Celine
    Baris, Vianney
    Laplante, Pierre
    Kannouche, Patricia
    Marty, Virginie
    Lacroix-Triki, Magali
    Dieras, Veronique
    Andre, Fabrice
    NATURE MEDICINE, 2023, 29 (08) : 2110 - +
  • [49] Fam-Trastuzumab Deruxtecan-nxki in metastatic HER2-low breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (07) : 779 - 779
  • [50] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB DERUXTECAN FOR PATIENTS WITH HER2+METASTATIC BREAST CANCER
    Mudumba, R.
    Chan, H.
    Cheng, Y. Y.
    Wang, C. C.
    Correia, L.
    Ballreich, J.
    Levy, J.
    VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
12345